Bulk Inquiry
MLN2238
- Ixazomib
Axon 2556
CAS:
1072833-77-2
Purity:
98%
- Soluble in DMSO
- MF: C14H19BCl2N2O4
- MW: 361.03
Description
Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.
MLN2238 is also available as the more stable citrate prodrug MLN9708 (Axon 2557).
More Information
| Parent CAS No. | 1072833-77-2 |
|---|---|
| Chemical Name | (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid |
| MFCD | N.A. |
| Short Description | Proteasome inhibitor |
References
- JJ Gu et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive….Anticancer Drugs. 2013 Nov;24(10):1030-8.
- EC Lee et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011 Dec 1;17(23):7313-23.
- N Shah et al. Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma. Exp. Opin. Orph. Drugs (2016), 4(1), 105-113.
Other Categories
Get a Quote for
Loading...